SCHEMBL5544630

SCHEMBL5544630

[O]c1ccc2c(c1)OCC2=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 10/20 0.47
MAOA P21397 5/20 0.47
MAPT P10636 5/20 0.46
HSD17B10 Q99714 3/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
KDM4E B2RXH2 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
CYP2C9 P11712 2/20 0.40
ALDH1A1 P00352 1/20 0.40
PSMB5 P28074 1/20 0.40
GRM5 P41594 1/20 0.36
NPC1 O15118 1/20 0.36
CYP1A2 P05177 1/20 0.36
PKM P14618 1/20 0.36
CYP2C19 P33261 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MIF P14174 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5539912 0.83 HSD17B10 (0.45) MAOBMAOAMAPTHSD17B10MEN1
SCHEMBL563933 0.78 MAOB (0.68) MAOBMAOAMAPTHSD17B10MEN1
SCHEMBL1924055 0.78 MAOB (0.54) MAOBMAOAMAPTHSD17B10MEN1
SCHEMBL568794 0.78 MAPT (0.57) MAOBMAOAMAPTHSD17B10MEN1
SCHEMBL2227219 0.78 MAOB (0.46) MAOBMAOAMAPTHSD17B10MEN1
SCHEMBL2056164 0.78 MAOB (0.54) MAOBMAOAMAPTHSD17B10MEN1
SCHEMBL1429041 0.78 MAOB (0.46) MAOBMAOAMAPTHSD17B10MEN1
SCHEMBL2491940 0.78 MAPT (0.52) MAOBMAOAMAPTHSD17B10MEN1
Hydrochloric Acid SCHEMBL2227227 0.76 MAOB (0.45) MAOBMAOAMAPTHSD17B10MEN1
SCHEMBL69427 0.73 MAOB (0.43) MAOBMAOAMAPTHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAOB 2140/4885MAOA 2885/4885MAPT 4117/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.